A newly engineered gene-editing enzyme could mark the beginning of a new chapter for CRISPR therapies — one where treatments reach cells directly inside the human body rather than requiring extraction and reinfusion.

Researchers at the University of Texas at Austin, funded by the National Institutes of Health, announced on April 13 that they have identified and optimized a naturally occurring enzyme called Al3Cas12f that is compact enough to be packaged into adeno-associated virus (AAV) vectors, the leading delivery vehicle for gene therapies. When enhanced through protein engineering, the enzyme achieved gene-editing efficiency rates of more than 80 percent across multiple targets — and hit 90 percent in one commonly edited genomic region.

That performance leap is dramatic. The unmodified enzyme edited at rates below 10 percent. The engineered variant, dubbed Al3Cas12f RKK, represents a tenfold improvement that could reshape the landscape of what gene therapy can target.

Why Size Matters

The most widely used CRISPR systems rely on the Cas9 protein, which works well but has a physical problem: it is too large to fit inside AAV vectors. Those vectors are the gold standard for delivering genetic payloads to specific cells inside the body, and their size limit has constrained CRISPR therapies to cells that can be removed, edited in a lab, and returned to the patient — primarily blood and bone marrow cells.

Diseases affecting the brain, liver, lungs, and other organs have remained largely out of reach for CRISPR treatment, not because the editing technology lacked precision but because there was no efficient way to deliver it.

Al3Cas12f changes that equation. Using imaging and machine learning tools, the UT Austin team analyzed why this particular enzyme works so well despite its small size. They found it forms a more stable, tightly connected molecular complex than similar compact enzymes, essentially arriving 'preassembled and ready to go' once produced inside cells.

From Lab to Clinical Potential

The team tested Al3Cas12f RKK in a human cell line originally isolated from a leukemia patient, targeting genes associated with cancer, atherosclerosis, and amyotrophic lateral sclerosis (ALS). The results were consistent and striking.

'Smart delivery of gene editing systems is a powerful notion with broad clinical implications, and this basic science finding takes us a significant step toward that future,' said Erica Brown, acting director of NIH's National Institute of General Medical Sciences.

The next step is testing the enzyme packaged inside actual AAV vectors — the critical proof-of-concept that would demonstrate the system can work as an injectable therapy. If those tests succeed, diseases from certain cancers to neurological conditions could become candidates for direct, in-body gene editing.

The Bigger Picture

CRISPR technology has transformed molecular biology since its gene-editing potential was first demonstrated in 2012. Treatments using the technology have already been approved for sickle cell disease, and clinical trials are underway for conditions ranging from hereditary blindness to high cholesterol.

But the delivery bottleneck has remained the field's most stubborn technical barrier. The Al3Cas12f breakthrough does not solve it entirely, but it removes one of the largest obstacles between the laboratory and the clinic.

The research was published in Nature Structural & Molecular Biology and supported by NIH grant R35GM138348.